Claudio D’Angelo, former co-founder and co-managing partner of Ryse Asset Management, has launched a new venture – an investment management firm designed to help digital healthcare and medtech start-ups deliver breakthroughs in healthcare systems.

With an initial fundraising target of £100 million and a starting portfolio of seven companies, Spex Capital will identify, support, and invest in early-stage digital health companies, allowing them to commercialise and scale within the NHS and other healthcare delivery systems on a global scale. The firm will invest in early stage and series A / B companies, offering tickets up to £5,000,000. 

Spex Capital kicks off with a team of 12 in place, made up of five investment team members and seven senior advisors. The team of senior advisors has been carefully chosen on the calibre of their backgrounds and complementary skills in the sector.

Claudio D’Angelo has personally made nine investments in seven target companies which now form Spex Capital’s current portfolio. The majority of these technologies have proven incredibly resilient to the current pandemic environment, have gained market share and are accelerating fund raising for further technological and geographical expansion.  

Through its central hub in London and thanks to its ongoing relationship with MedCity, Spex Capital benefits from connections to the NHS in England and several other stakeholders.  

Claudio D’Angelo, co-founder and managing director of Spex Capital, said: “Spex, from specere, latin verb for 'to look at’, defines who we are. As thorough observers, we analyse potential investee companies scrupulously, carrying out a detailed due diligence in order to efficiently select and invest in them. Following my experience with Ryse Asset Management, I decided to launch a more ambitious venture both in terms of scale and geographical focus. 

“Many innovative ventures in the digital health and medtech sector don't get access to the appropriate opportunities in their early stages due to lack of funds and investors tending to favour business models with a longer track record. There is, however, an incredible pool of talent with unexpressed potential. This is where Spex comes in.

“Specialised in advancing disruptive early-stage ventures, our goal is to deliver breakthroughs in healthcare systems globally. 

“Thank you MedCity for the support and thank you also to the incredible team that has chosen to join me in this exciting journey.”